Yttrium 90-labelled edotreotide(Yttrium 90-labelled edotreotide) - 药物靶点：SSTR_在研适应症：神经内分泌肿瘤_专利_临床

概要

基本信息

药物类型

多肽偶联核素

别名

90Y-DOTA-D-Phe1-Tyr3-octreotide、OctreoTher、Onalta

+ [7]

靶点

SSTR

作用机制

SSTR激动剂(生长抑素受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

University of IowaNovartis Pharma AG

非在研机构

Molecular Insight Pharmaceuticals, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C65H89N14O18S2Y

InChIKeyDUSFGVAHRFYHFD-IEOVAKBOSA-K

CAS号189758-25-6

使用我们的XDC技术数据为新药研发加速。

登录

或

查看完整样例数据

序列信息

Sequence Code 526980110

来源: *****

关联

9

项与 Yttrium 90-labelled edotreotide 相关的临床试验

NCT03724409 / Terminated早期临床1期IIT

Selective Intra-arterial Injection of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumor Patients With Liver Metastases

This is a safety study to determine the phase 1 starting dose of [90]Yttrium-DOTATOC when it is administered intravenously for patients with neuroendocrine tumors that have spread to the liver.

开始日期2018-10-11

申办/合作机构

University of Iowa

[+3]

NCT03197012 / Completed早期临床1期IIT

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery.
Participants in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose, and undergo additional imaging and assessment.

开始日期2017-07-01

申办/合作机构

The University of California, San Francisco

NCT03044977 / Active, not recruiting早期临床1期IIT

Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.

This study is designed to identify the best tolerated doses of [131]Iodine-MIBG and [90]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated doses of these drugs (when combined together) is unknown.

开始日期2017-05-07

申办/合作机构

University of Iowa

[+3]

100 项与 Yttrium 90-labelled edotreotide 相关的临床结果

登录后查看更多信息

100 项与 Yttrium 90-labelled edotreotide 相关的转化医学

登录后查看更多信息

100 项与 Yttrium 90-labelled edotreotide 相关的专利（医药）

登录后查看更多信息

136

项与 Yttrium 90-labelled edotreotide 相关的文献（医药）

2024-07-01·Journal of Vascular and Interventional Radiology

Outcomes in Patients with Macrotrabecular-Massive Subtype Hepatocellular Carcinoma Treated with Yttrium-90 Transarterial Radioembolization

Article

作者: Balli, Huseyin Tugsan ; Erdoğan, Kivilcim Eren ; Piskin, Ferhat Can ; Sozutok, Sinan ; Aikimbaev, Kairgeldy

PURPOSETo compare the outcomes of yttrium-90 transarterial radioembolization (TARE) in patients with hepatocellular carcinoma (HCC) with and without macrotrabecular-massive (MTM) subtypes.MATERIALS AND METHODSForty-one consecutive patients with HCC (male, 90.3%; mean age, 65.3 years [SD ± 10.7]) who underwent yttrium-90 TARE between September 2014 and January 2022 were grouped into the MTM-HCC (n = 17, 41.5%) and non-MTM-HCC (n = 24, 58.5%) groups based on their histopathological subtypes. Demographic, clinical, and radiological characteristics were compared. Survival, univariate, and multivariate analyses were performed, and prognostic factors were evaluated.RESULTSIn MTM-HCC group, the rates of moderately to poorly differentiated tumors were significantly higher (13/17 vs 8/16, P = .007), and new intrahepatic/extrahepatic metastases were detected more frequently (12/17 vs 15/24, P = .038). Median overall survival (OS) in the cohort was 29 months (range, 17.1-40.9 months), whereas patients with MTM-HCC had a significantly shorter median OS (20 vs 44 months, P = .014). In univariate analysis, MTM-HCC subtype (hazard ratio [HR], 2.690; P = .021), the presence of satellite nodules (HR, 3.810; P = .004), and macrovascular invasion (HR, 3.321; P = .012) were identified as significant prognostic factors. In multivariate analysis, MTM-HCC subtype and macrovascular invasion were determined as independent poor prognostic factors (P = .038 and P = .012, respectively).CONCLUSIONSIn patients with HCC treated with yttrium-90 TARE, both the rates of moderately to poorly differentiated histopathological classes and the development of intrahepatic or extrahepatic metastases were significantly higher in the MTM-HCC subtype. OS was worse in patients with MTM-HCC, and macrovascular invasion and MTM-HCC subtype were identified as independent poor prognostic factors.

2023-09-01·Journal of neuro-oncology

Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.

Article

作者: Heugenhauser, Johanna ; Scherfler, Christoph ; Iglseder, Sarah ; Nevinny-Stickel, Meinhard ; Uprimny, Christian ; Iglseder, Anna ; Kerschbaumer, Johannes ; Stockhammer, Guenther ; Virgolini, Irene ; Dudas, Jozsef ; Nowosielski, Martha ; Beliveau, Vincent ; Gizewski, Elke R

OBJECTIVEThis retrospective study aimed to analyse the correlation between somatostatin receptor subtypes (SSTR 1-5) and maximum standardized uptake value (SUV_max) in meningioma patients using Gallium-68 DOTA-D-Phe1-Tyr3-octreotide Positron Emission Tomography ([68Ga]Ga-DOTATOC PET). Secondly, we developed a radiomic model based on apparent diffusion coefficient (ADC) maps derived from diffusion weighted magnetic resonance images (DWI MRI) to reproduce SUV_max.METHODThe study included 51 patients who underwent MRI and [68Ga]Ga-DOTATOC PET before meningioma surgery. SUV_max values were quantified from PET images and tumour areas were segmented on post-contrast T1-weighted MRI and mapped to ADC maps. A total of 1940 radiomic features were extracted from the tumour area on each ADC map. A random forest regression model was trained to predict SUV_max and the model's performance was evaluated using repeated nested cross-validation. The expression of SSTR subtypes was quantified in 18 surgical specimens and compared to SUV_max values.RESULTSThe random forest regression model successfully predicted SUV_max values with a significant correlation observed in all 100 repeats (p < 0.05). The mean Pearson's r was 0.42 ± 0.07 SD, and the root mean square error (RMSE) was 28.46 ± 0.16. SSTR subtypes 2A, 2B, and 5 showed significant correlations with SUV_max values (p < 0.001, R2 = 0.669; p = 0.001, R2 = 0.393; and p = 0.012, R2 = 0.235, respectively).CONCLUSIONSSTR subtypes 2A, 2B, and 5 correlated significantly with SUV_max in meningioma patients. The developed radiomic model based on ADC maps effectively reproduces SUV_max using [68Ga]Ga-DOTATOC PET.

2023-05-01·Clinical Nuclear Medicine

Differentiation of a Falcine Meningioma From Cerebral Venous Sinus Thrombosis Using DOTATATE PET

Article

作者: Schlamann, Marc ; Drzezga, Alexander ; Werner, Jan-Michael ; Schroeter, Michael ; Schmidt, Matthias ; Baumann, Claudia ; Fink, Gereon R ; Neuneier, Janina ; Stetter, Isabelle ; Galldiks, Norbert

AbstractDifferentiating brain tumors from nonneoplastic lesions using conventional MRI may be challenging. Clinical symptoms often remain unspecific, and imaging findings from MRI may be inconclusive. We present the case of a 23-year-old woman in whom an MRI suggested a cerebral venous sinus thrombosis. On the other hand, additional atypical MRI findings raised doubts regarding the initial diagnosis. Given the need for a diagnostic procedure with higher sensitivity and specificity for neoplastic tissue, PET with the radiolabeled somatostatin receptor ligand DOTATATE (68Ga-DOTA-d-Phe1-Tyr3-octreotate) was performed. DOTATATE PET facilitated the diagnosis of a falcine meningioma consistent with its value for the differential diagnosis of meningioma.

100 项与 Yttrium 90-labelled edotreotide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
消化道恶性类癌	临床2期	-	Molecular Insight Pharmaceuticals, Inc.	2008-06-01
神经内分泌肿瘤	临床2期	-	Novartis Pharma AG	-
神经内分泌肿瘤	临床2期	-	University of Iowa	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2004	N/A	神经内分泌肿瘤	60	[Y-90-DOTA,Tyr3]octreotide (4-cycle regimen)	網製夢繭鏇壓衊蓋願窪(憲鹹選製築網淵願製選) = 鏇鏇醖選窪簾窪廠鹽壓顧衊構網遞夢廠簾艱壓 (築築遞襯範襯鏇夢範淵, 38% less than baseline) 更多	-	2004-07-15
				[Y-90-DOTA,Tyr3]octreotide (single-cycle regimen)	網製夢繭鏇壓衊蓋願窪(憲鹹選製築網淵願製選) = 蓋窪範廠鹹糧選觸繭鏇顧衊構網遞夢廠簾艱壓 (築築遞襯範襯鏇夢範淵, 27% less than baseline) 更多